Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV(1) level: a patient-level pooled analysis of phase-3 randomized clinical trials

BACKGROUND: Which patients should receive dual therapy as initial treatment for chronic obstructive pulmonary disease (COPD) is only loosely defined. We evaluated if a lower forced expiratory volume in 1 s (FEV(1)) identifies a population more likely to benefit from dual therapy than monotherapy amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jieun, Lee, Jae Seung, Lee, Sei Won, Lee, Jung Bok, Oh, Yeon-Mok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881547/
https://www.ncbi.nlm.nih.gov/pubmed/33579288
http://dx.doi.org/10.1186/s12931-021-01648-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881547/
https://www.ncbi.nlm.nih.gov/pubmed/33579288
http://dx.doi.org/10.1186/s12931-021-01648-5

Ejemplares similares